Market Research Blog

[341 Pages Report] Cancer, cardiovascular diseases, and metabolic diseases like diabetes, are the main cause of mortality and disability in present times. Even with the understanding of scientific disease indications, it is crucial to elevate diagnosis and control the symptoms and signs of illness.

According to the Future Market Insights’ analysis, the injectable drugs market is set to grow at a 5.8% CAGR over the assessment period. As per the report, the market is projected to be valued at US$ 937.0 Bn by the end of 2032.

Advancements in technologies that involve optimization of the devices used for clinical conditions, be it chronic or acute, clinical innovations, bringing in minimally invasive treatments, and evolvement in clinical diagnostics and management in treating high-risk patients, are the key developments within the general healthcare industry.

To remain ahead of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15073

Demand for related treatments is increasing, as people are now more aware of the right treatment options, doctor-guided plans, and precautionary measures to consider for serious clinical conditions.

Key players in the injectable drugs market are actively seeking to gain approvals from regulatory bodies, and develop products across the continuum of care in severe case recovery. Furthermore, the FDA is expected to approve new devices related to advanced injectable drugs and their administration, over the coming years.

“Increasing incidence of infectious diseases, oncological diseases, cardiac disorders and device innovation are prompting healthcare providers to incorporate new treatment regimens for improved patient outcome,” says an FMI analyst.

Key Takeaways:

• By product, monoclonal antibodies held the largest share of 5% in the global market in 2021.
• Based on application, infectious diseases segment held the largest share of 4% in the global market in 2021, with the segment expected to expand at 5.7% CAGR over the forecast period.
• In terms of molecule, large molecule segment held the largest share of 8% in the global market in 2021.
• By route of administration, sales in the intravenous (IV) segment are expected to increase at a 3% CAGR over the assessment period.
• Based on distribution channel, the hospital pharmacies segment was valued at US$ 231.0 Bn in 2021.
• North America held the largest share of 5% in the global injectable drugs treatment market in 2021, owing to the growing government investments in healthcare and R&D activities.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15073

Competitive Landscape

Product launches and collaborations with suppliers that have a strong position and are popular in the market are some of the key strategies of the market players operating in the global injectable drugs market. For instance:

• Merck and Gilead Sciences, Inc. (Gilead) signed an agreement in March 2021 to collaborate on the development and commercialization of long-acting HIV treatments that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s investigational capsid inhibitor lenacapavir.
• In March 2022, Sanofi IGM Biosciences, Inc. today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.
• In February 2022, Novartis India Limited extends access to its medicines in India by signing exclusive sales and distribution agreement with Dr. Reddy’s Laboratories

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the injectable drugs market in its latest study, presenting a historical demand assessment of 2014 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (monoclonal antibodies, immunoglobulin, cytokines, insulin, peptide hormones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), by application (oncology, infectious diseases, diabetes, blood disorders, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management, and cardiovascular diseases), by molecule type (small molecules and large molecules), by route of administration (intravenous (IV), intramuscular (IM), and subcutaneous (SC)), by distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies), across seven key regions of the world.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-15073

Key Players :

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca Plc
• Merck & Co., Inc.
• Viatris + Mylan N.V
• Cipla Inc.
• Dr. Reddy’s Laboratories Ltd.
• Samsung Biologics
• Abbott Laboratories
• Amgen Incorporated
• Baxter International Incorporated
• Becton Dickinson and Company
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Roche Holding Limited

Key Segments Covered in Injectable Drugs Industry Research

By Product:

• Monoclonal Antibodies
• Immunoglobulin
• Cytokines
• Insulin
• Peptide Hormones
• Blood Factors
• Peptide Antibiotics
• Vaccines
• Small Molecule Antibiotics
• Chemotherapy Agents
• Others

By Application:

• Oncology
• Infectious Diseases
• Diabetes
• Blood disorders
• Hormonal Disorders
• Musculoskeletal Disorders
• CNS Diseases
• Pain Management
• Cardiovascular Diseases

By Molecule Type:

• Small Molecules
• Large Molecules

By Route of Administration:

• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain

Legionnaire Disease Testing Market Trends : The legionnaire disease testing market is projected to register a CAGR of 9% during the forecast period, up from US$ 292 Mn in 2022 to reach a valuation of US$ 819.5 Mn by 2032.

Electronic Tongue Market Outlook :  The electronic tongue market is anticipated to record a CAGR of 4.5% during the forecast period (2022-2032).

Injectable Drugs Market Type : The global injectable drugs market is expected to reach US$ 531.8 Bn in 2022. Sales in the market will increase at a CAGR of 5.8%, reaching US$ 937.0 Bn by 2032.

Intubation Tube Market Size : The estimated market growth between 2022 and 2032, at 6.8%, is expected to be higher than historical growth.

3D Printed Surgical Models Market Share : 3D Printed Surgical Models Market in 2021 was held at US$ 347 Mn. With 18.7%, the projected market growth during 2022 – 2032 is expected to be significantly higher than the historical growth.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[228 Pages Report] According to the analyst of Future Market Insights (FMI), the leading manufacturers of connected drug delivery devices are focusing collaboration with the software companies to assess the cloud data system in their devices.

The market for connected drug delivery devices is foreseen to witness a stellar growth rate of 25.6% from 2013 to 2028 rising to a valuation of US$ 1,304.7 Mn from US$ 132.2 Mn in 2022.

Moreover, it helps the manufacturer to launch the product more conveniently and to enhance their distribution channel. Manufacturers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

The companies operating in the global connected drug delivery devices market are OPKO Health Inc., Bayer AG, 3M Company, West Pharmaceutical Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.

Rapidly evolving technologies, for instance, cloud-based computing models, are enabling the healthcare industry towards a transition to a new architecture.

Cloud technology along with advances in mobility and telepresence solutions is expected to create new unwired business models capable of providing healthcare anywhere.

The use of cloud technology will increase, aided by the proliferation of mobile health applications to collect and send vital signs from wireless and wired remote patient and personal health monitoring devices. Cloud-based platforms and new IT service models will fundamentally change the healthcare business equations and create opportunities for new players to enter the industry.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2755

Growing Demand for Injectable Drug Delivery to Aid Market Growth

The rising preference for injectable drug delivery is anticipated to drive the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes

Following this opportunity, the manufacturers are expected to cash in on profits through introduction of smart injectable drug delivery mediums among their portfolio. The progress is expected to be more prominent in the allergic reactions (Anaphylaxis) indication segment. Further, an upsurge in the number of large molecule drugs that need to be manufactured in injectable format is expected to fuel the growth of the market. Likewise, data generated by bioavailability studies is proving to present a definitive relation between pharmacodynamics and pharmacokinetics for such sterile drugs, which is also expected to offer support to the growth of the market.

Mobile applications are also being used for the treatment of patients suffering from Alzheimer, Diabetes, COPD or Asthma. Mobile applications with the use of GPS help to track the patient location. If the patient is travelling away from the home, the caretaker can track the exact location of the patient and also track the consumption of dosage by using mobile application. Most of these applications have been developed for the cloud. Placing the wireless solution on a cloud storage system helps with connectivity issues and makes it easier to communicate across different information regimes.

Limited Knowledge and Adoption Rate among Patients to Hinder Growth Rate

The deployment of connected drug delivery devices is not yet widely promoted within the public health system. This is attributed to the high cost of the product, limited reimbursement, and dearth of awareness among the patients regarding the technology. Moreover, complexity and limited availability of the device further reduces penetration. For instance, interpretation of insulin delivery trend for analysis, is considered to be useful however, because of the complicated user interface, the patients cannot interpret them smoothly. As per the current scenario, such obstacles might directly have an adverse effect on the overall growth of the connected drug delivery devices market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2755

Key Segments of Connected Drug Delivery Devices Industry Survey Connected Drug Delivery Devices Market by Product Type:

• Inhalation Devices
• Injectable Devices
  • Handheld Injectable Devices
  • Wearable Injectable Devices

Connected Drug Delivery Devices Market by End User:

• Hospitals
• Clinics
• Home Care

Connected Drug Delivery Devices Market by Application:

• Anaphylaxis
• Cardiovascular
• Diabetes
• Hormone Replacement
• Others

Connected Drug Delivery Devices Market by Technology:

• Bluetooth Drug Delivery Devices
• Near Field Communication Drug Delivery Devices

Connected Drug Delivery Devices Market by Region:

• North America Connected Drug Delivery Devices Market
• Latin America Connected Drug Delivery Devices Market
• Europe Connected Drug Delivery Devices Market
• East Asia Connected Drug Delivery Devices Market
• South Asia & Pacific Connected Drug Delivery Devices Market
• Middle East & Africa (MEA) Connected Drug Delivery Devices Market

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

According to a recent report by Future Market Insights (FMI), rising prevalence of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) is expected to boost the growth opportunities for female pelvic implants market. The market is set to reach a valuation of US$ 245 Mn in 2021, rising at a CAGR of 2.8% through the end of 2031.

According to the American Urological Association (AUA/SUFU), the incidence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The incidence of stress urinary incontinence is high in women with poor or weakened pelvic supports. This disease affects the lives of women to a great extent and is widespread in the older population.

Increasing incidence of vaginal disorders among aged women coupled with the non-availability of other treatment options for SUI and POP will continue increasing the demand in the female pelvic implants market. According to the U.S. FDA, the number of women who have POP is estimated to surge by 46%, to 4.9 million, by 2050.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3422

However, the low rate of efficacy after pelvic implantation and the problems of pelvic organ prolapse are hampering the growth of the female pelvic implants market.  COVID-19 is anticipated to have a moderately negative impact on the female pelvic implants market due to implementation of lockdown. Supplies and demand were jolted by the massive spread of the infection, which staggered the growth of the female pelvic implants market.

Key Takeaways from Female Pelvic Implants Market Study

• Vaginal sling/tapes demand is anticipated to gain maximum revenue share of more than 68%, rising at an expected CAGR of 2.5% owing to the high demand to treat stress urinary incontinence.
• Hospitals followed by ambulatory surgical centers are leading users of female pelvic implants growing owing to the rising number of POP and SUI patients.
• The U.S. accounts for more than 83% of the North America market, driven by the high incidence of pelvic organ prolapse.
• The U.K.is a leading market in Europe. It is expected to account for nearly 13% of demand registered in Europe by 2031. Implementation of government funded awareness programs will remain a chief growth driver.
• Over 30% of the South Asia market is held by India. Growth in the country is propelled by significant investments in the expansion of healthcare sector.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3422

Post-Marketing Surveillance of Approved Devices Influencing Female Pelvic Implants Demand

An increasing number of manufacturers are continuing to sell their products in the global market despite restrictions by law. After the FDA reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies to assess impacts of organ damage and other complications of mesh implants.

After assessing the risks, manufacturers can reintroduce their devices and can get pre-market approval from the FDA. This allows manufacturers to re-launch the mesh implants, which is expected to come into the market by 2022.

Who is Winning?

Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to strengthen their product portfolios in the female pelvic implants market.

For instance, Coloplast acquired Nine Continents Medical, Inc. in November 2020 and aimed to expand its medical device product portfolio.

The FDA, in 2019 completed its broad evaluation of data associated with the resin used in the production of Boston Scientific’s vaginal mesh through which, the US federal law limits these devices to sale by order of a surgeon.

Want More Insights?

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Female Pelvic Implants Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the Female Pelvic Implants Market on basis of product type [Vaginal Mesh Implants, Vaginal Sling/Tape and Vaginal Graft Implants], Indication [Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)]. Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3422

Market Taxonomy Product Type

• Vaginal Mesh Implants
• Vaginal Sling
• Vaginal Graft Implants

Indication

• Pelvic Organ Prolapse
• Stress Urinary Incontinence

End User

• Hospitals
• Ambulatory Surgical Centres
• Speciality Clinics

Region

• North America
• Latin America
• China
• Western Europe
• Eastern Europe
• APECJ
• Japan
• MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The Exosomes Diagnostic and Therapeutic Market is estimated at USD 58.6 million in 2022 and is projected to reach USD 175.4 million by 2028, growing at a CAGR of 20.0% during the forecast period (2022-2028).

Future Market Insights in its recent research report titled “Exosome Diagnostic and Therapeutics Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” covers several factors that are influencing the robust growth of the global market. As per this research report, the global exosome diagnostic and therapeutic market is projected to expand at a high CAGR of 23.1% during the period of assessment.

The exhaustive research publication includes key trends, opportunities, threats, growth drivers and challenges that impact the global exosome diagnostic and therapeutics market. Detailed pricing analysis of different exosome diagnostic and therapeutics across key regions is also discussed in the research study. The segmental analysis across North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Latin America, Japan and Middle East and Africa (MEA) is carried out which is used to track the future projections for a period of ten years, pertaining to value, of the global exosome diagnostic and therapeutics market.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-6379

Global Market for Exosome Diagnostic and Therapeutics: Underlying Forces Influencing Growth

The growth of global market for exosome diagnostics and therapeutics is influenced by several factors. Increasing need for screening and diagnosis of chronic diseases coupled with high therapeutic potential of exosomes are fuelling the adoption of exosome diagnostics and therapeutics. Moreover, introduction of explicit systems for analysis of proteins specific to exosomes, increasing research and development activities supported by favourable government policies across various regions and increasing popularity of exosome over CTC and ctDNA are expected to trigger the growth of the global market for exosome diagnostic and therapeutics market in the years to follow. On the contrary, lack of standardization and validation requirements for isolation of exosomes is expected to pose hindrances to the growth of the global market. Other factors negatively impacting the market’s growth include heavy investments in research and development and insufficient insurance coverage of costly cancer diagnostic tests.

Segmentation Highlights of the Global Exosome Diagnostic and Therapeutics Market

The global exosome diagnostic and therapeutics market is segmented on the basis of product type, application, end user and region.

In the region category, North America is estimated to be the largest with a high market lucrativeness. This region is expected to grow at a significant CAGR during the forecast period to touch a large market estimation by end of the assessment year, thus leading the global market. Moreover, Asia Pacific excluding Japan (APEJ) is the fastest growing region and is the second largest in terms of adoption and use of exosome diagnostics and therapeutics. APEJ is filled with high growth opportunities and is being targeted by several giants in this sector, such as Thermo Fisher Scientific.

By product type, reagents and kits are gaining high traction owing to increasing use in exosome diagnostics and therapeutics. The reagents and kits segment dominated the market in 2017 and is anticipated to continue with the trend in the coming years. This segment is also expected to expand at a high growth rate during the forecast period. The reagents and kits segment is expected to register a high CAGR of 28.2% throughout the period of forecast. The software segment is the second fastest growing segment spurring the growth of the global market.

In the application category, diagnostic segment is the largest as compared to therapeutics segment and is estimated to touch a value of over US$ 90 Mn by the end of the year of assessment, growing at a significant pace. Therapeutics segment is projected to expand at a CAGR of 29.0% throughout the period of assessment.

With respect to end user, the use of exosome diagnostic and therapeutics is largely observed in diagnostic centres. The diagnostic centres segment is expected to surpass other end user segments with a high market share and growth rate in the coming years.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6379

Forecast Analysis of the Global Exosome Diagnostic and Therapeutics Market

According to the research report, the global market for exosome diagnostic and therapeutics is expected to grow at a high CAGR to reach an estimate of over US$ 150 Mn by the end of the year of assessment from a value of about US$ 19 Mn in 2017.

Competitive Landscape Shaping the Global Exosome Diagnostic and Therapeutics Market

Manufacturers of exosome diagnostic and therapeutics are focusing to raise capital required for launch of new products or research and development expenses through venture financing. Key companies such as

• Thermo Fisher Scientific Inc.
• NanoSomix Inc.
• NX PHARMAGEN
• Capricor Therapeutics Inc.
• Exosome Diagnostics Inc.
• Exiqon A/S (Aethlon Medical Inc.).
• System Biosciences Inc.
• Aegle Therapeutics AMS Biotechnology (Europe) Limited
• Miltenyi Biotec.

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-6379

Market segmentation

By Product Type

• • Instrument
• Software
• Reagents and Kits

By Application

• Diagnostics
• Therapeutics

By End User

• Hospitals
• Cancer Institutes
• Diagnostic Centres
• Others

By Region

• North America
• Latin America
• Eastern Europe
• Western Europe
• Asia Pacific excluding Japan
• Japan
• Middle East and Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[297 Pages Report] The global IoT in healthcare market is projected to reach US$ 181.4 Billion in 2022, anticipated to grow at a CAGR of 18.0%, reaching US$ 952.3 Billion by 2032. The market is slated to document a Y-o-Y growth rate of 20.7% from 2021-2022, increasing from the previously registered value of US$ 150.3 Billion.

By enabling real-time patient data access and remote patient monitoring, the Internet of Things (IoT) has the potential to disrupt traditional paper-based healthcare therapy. With the emergence of this digital healthcare technology, the impending need for enhanced diagnostics and targeted therapeutic options was met.

Furthermore, it not only enables physicians to remotely monitor patients, but it also functions as a fitness and wellness tracker for athletes and a dose reminder for patients. The successful implementation of IoT in remote monitoring of diabetic and asthma patients, along with the growing usage of fitness and wellness devices, has resulted in a considerable demand for the IoT healthcare business.

Download FREE Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14639

Key Takeaways from the Market Study
•IoT in healthcare experienced a growth rate worth 18.8% between 2015 and 2021

• Portable diagnostic devices in the IoT in Healthcare segment to expand at a CAGR of 10.1% during the forecast period
• In the U.S., the market is predicted to reach US$ 208.1 Billion while growing at a CAGR of 18.9% during the forecast period
• China’s market is expected to reach a market value of US$ 92.8 Billion with a CAGR of 19.5% during the forecast period

“Big data analytics is an area of IoT that is quickly expanding. The most recent breakthroughs in machine learning, logical procedures, computational intelligence, and data mining are required for big data analytics”, says an FMI analyst.

Competitive Landscape

Ask for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14639

Key players that have been profiled in the report are Apple Inc., Cisco Systems Inc., GE Healthcare Ltd., Google (Alphabet), International Business Machines
Corporation, Medtronic PLC, Microsoft Corporation, Proteus Digital Health, Koninklijke Philips N.V., QUALCOMM Incorporated, and Abbot Laboratories are among companies that offer products and technologies that will allow customers to take advantage of new technologies.

• In April 2019, Royal Philips and Spencer Health Solutions expanded their relationship to provide chronically sick patients in selected European Union (EU) nations with in-home medication adherence and the Philips telehealth platform.
• Medtronic worked with IBM Watson in January 2019 to provide IQcast, a new feature of its current product Sugar.IQ, for iOS mobile devices in the United States. The software would provide patients with a hypoglycemic episode to monitor their low glucose level by anticipating the occurrence 1 to 4 hours in advance.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

According to the latest research by Future Market Insights (FMI), the global market for medical physics will exceed the valuation of US$ 6 billion towards the end of projection period.

Prominently driven by the growth of medical tourism sector and increasing expanse of diagnostics, the global revenue of medical physics market will reportedly thrive at a healthy over-6% CAGR during 2018-2028. Growing adoption of nuclear medicine has also been cited as an important factor responsible for a positive growth outlook anticipated for medical physics market.

However, the report also highlights that the insufficient availability of skilled workers and relatively poor healthcare infrastructure for medical physicist trainings in developing regional markets will continue to restrict penetration of medical physics in the long run.

To remain ‘ahead’ of your competitors, request for a sample https://www.futuremarketinsights.com/reports/sample/rep-gb-5274

The ‘Outsourcing’ Trend Is Creating Firm Base for Merger & Acquisition Strategies

With the consolidation of hospitals, there is an increasing need for larger firms in the medical physics market, with an intent to handle the outsourced services so as to contract with fewer services providers. The medical physics market is characterised by the presence of small independent companies, and there is a negligible number of large-scale operators. According to the report, this presents opportunities for private equity firms to enter the middle-market platform and scale-up their medium-scale operations to large-scale operations through the acquisition of smaller firms.

Other factors driving mergers and acquisitions in the medical physics market include increasing stringent regulations and an increasing number of owners looking to exit the medical physics business. Increasing stringent regulations have resulted in the inspection of a larger number of machines and associated elements. Several healthcare systems are incurring higher risks due to the increasingly stringent regulations. This opens opportunities for medical physics companies to ensure compliance and reduce operation cost by outsourcing. Furthermore, most of the medical physics firms are owned and operated by baby boomers who are about to retire from their medical physics business. For a majority of those medical physics service providers who are retiring, selling their business has been considered to be the most preferred option.

Some of the other trends in the medical physics market include increased outsourcing by healthcare providers, increasing number of independent diagnostic imaging centres, and advancements & adoption of technology across the world.
Segmental Insights: Medical Physics Market

Diagnostic modality, driven by increasing adoption of diagnostic procedures such as PET, SPECT, CT, and MRI, will continue to account for more than 65% share of the total medical physics market value.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-5274

Based on services, accreditation assistance is slated to remain dominant, followed by safety surveys. The report anticipates physics testing and regulatory and auditing services to emerge highly potential.

Following hospitals, diagnostic imaging centers are likely to register significant adoption rate in the medical physics market through 2027.

The North American and European medical physics market will reportedly account for a majority of market value, according to FMI’s analysis on medical physics market. The report has attributed this dominance to rapid consolidation of healthcare facilities in these regions.

Some of the key players in the medical physics market include Krueger-Gilbert Health Physics, Inc., LANDAUER, Medical Physics Services, Medical Physics Services Consultants, Inc., Alyzen Medical Physics Services, Radiation Safety & Control Services, Inc., Upstate Medical Physics Services, Dade Moeller & Associates, Versant Medical Physics Services & Radiation Safety, Alliance Medical Physics Services LLC, West Physics Consulting, LLC, Associates in Medical Physics Services, Radiation Services, Inc., Jaeger Corporation, and Petrone Associates, LLC.

Additional information on global medical physics market can be availed. Write to the analyst at press@futuremarketinsights.com

Global Medical Physics Market: Segmentation
Analysis by Modality

Diagnostic
Radiographic X-Ray Systems
Fluoroscopic X-Ray Systems
Dental X-Ray Systems
Mammography Systems
Computed Tomography
Magnetic Resonance Imaging
Ultrasound
SPECT
PET
Others
Therapeutic
LINAC
Brachytherapy
Others

Analysis by Service

Accreditation Assistance
Performance Testing
Physics Testing
Radiation Dose Monitoring
Radiation Safety Training
Treatment Commissioning Services
Safety Surveys
Regulatory and Auditing Services
Others

Analysis by End User

Hospitals
Ambulatory Surgical Centers
Diagnostic Imaging Centers
Academic and Research Institutes

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-5274
Analysis by Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

• A steady rise in global research and development expenditure
• Efforts to leverage the potential of 3D cell culture to replace animal model testing
• Increasing demand for biosimilar products
• Extensive application of stem cell research and a growing emphasis on regenerative medicine

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material – natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

“While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years,” says FMI.

Leading Manufacturers in the 3D Cell Culture Market:

• Thermo Fisher Scientific Inc.,
• Merck KGaA,
• Becton,
• Dickinson and Company, and Lonza,
• Corning Incorporated,
• Synthecon, Inc.

Competitive Landscape of the Global 3D Cell Culture Market

The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.

The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.

Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Key Segment Based on product type

• scaffold-free 3D cell culture
• scaffold-based 3D cell culture

Based on application

• drug discovery
• tissue regeneration & regenerative medicines
• cancer research
• stem cell technology
• others

Based on end user

• biotechnology and pharmaceuticals industries
• hospital laboratories
• academic research and institutes
• contract research organizations

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

According to the study, a number of broader, and industry-specific factors will drive growth in this market, which has been relatively less impacted by the sluggishness induced by COVID-19.

Global viscosuppplementation revenues are likely to reach USD 4 billion by the end of 2030, according to a new research by ESOMAR-certified firm Future Market Insights.

As per the UN, by 2050, those aged 60 and above will account for over 20% of the global population. In other words, the UN says that by 2050 around 130 Mn people will contract osteoarthritis. These numbers point towards growth in the viscosupplementation market in the forecast period.

Covid-19 Pandemic: Viscosuppplementation Market Players Consolidating their Position

The ongoing Covid-19 pandemic has compelled the market players to take a consistent path for the next two quarters. As it would take some time for the healthcare vertical to look through new product launches; the players are looking at ways to smoothen the supply chain as manpower has taken a hit.

Continuous innovations are expected to propel the growth of viscosupplementation market” says the FMI analyst

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9509

Key Takeaways of Viscosupplementation Market Study   

• Three injection viscosuppplementation is expected to contribute for more than 55% of revenue share
• Knee osteoarthritis is expected to gain around one-third of market share during the forecast period
• North America is the highest revenue generating market due to scientific advancements and high adoption of viscosuppplementation

New Product Development to be the Torchbearer

The market players are into the innovation mode to strengthen their foothold in the viscosupplementation market. This competitive landscape is all set to create ripples all across the market. Some of the innovations are:

• Fidia Pharma USA Inc., in 2019, introduced a HA (Hyaluronic Acid) based intra-articular viscosupplement called “TRILURON” to treat knee osteoarthritis. The treatments cycle involves 3 injections at weekly intervals.
• Japan-based Seikagaku Corporation, in Mar 2019, launched an intra-articular single-injection viscosupplement called “HyLink” in Italy for treating knee osteoarthritis.
• Recently, Gel-One Hyaluronate was approved as one of the injectable gels to treat osteoarthritis of knee. The pre-market clinical study reported no pseudosepsis (severe acute inflammatory responses).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9509

Want more insights?

Viscosupplementation market, a new study from Future Market Insights, opines on the viscosupplementation from 2015 – 2019 and presents demand projections from 2020 – 2030 on the basis of; product types (single injection viscosupplementation, three injection viscosupplementation, and five injection viscosupplementation), application (knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, and others such as elbow and ankle joint osteoarthritis), and end user (hospitals, ambulatory surgical centers, orthopedic clinics, retail pharmacies, and online sales) across seven prominent regions.

Viscosupplementation Market: Segmentation

The global viscosupplementation market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type

• Single Injection Viscosupplementation
• Three Injection Viscosupplementation
• Five Injection Viscosupplementation

Application

• Knee Oseteoarthritis
• Hip  Oseteoarthritis
• Shoulder Oseteoarthritis
• Others

Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs